SUBSCRIBE
SUBSCRIBE

UK Health Watchdog Again Rejects Roche’s Avastin

August 24, 2010 | 
1 min read

LONDON (Dow Jones)--The U.K.'s healthcare cost regulator Tuesday again said it wouldn’t recommend Roche Holding AG’s (ROG.VX) Avastin drug for advanced bowel cancer, despite the Swiss drug maker offering a fresh price deal.

Europe
Roche
MORE ON THIS TOPIC
Sign outside BioNTech's building in Germany
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
A handshake of businessmen. Modern design with a positive context. Concept of help, support, and agreement between businessmen. Modern art collage, trendy magazine style.
Mergers & acquisitions
Novo, Catalent $16.5B Deal Wins EU Blessing as US Antitrust Scrutiny Mounts
December 9, 2024
 · 
2 min read
 · 
Tristan Manalac
Facade of Novo Nordisk's office in Fremont, California
Manufacturing
Novo Continues Manufacturing Spending Spree With $400M Denmark Expansion, $200M Plant Purchase
December 5, 2024
 · 
2 min read
 · 
Tristan Manalac
Sanofi's Distribution Center in Quebec, Canada
Radiopharmaceuticals
Sanofi Inks $326M Radiopharma Deal With Orano
October 17, 2024
 · 
2 min read
 · 
Tristan Manalac